Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy


Onat A., Direskeneli H.

CURRENT PHARMACEUTICAL DESIGN, vol.18, no.11, pp.1465-1477, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 18 Issue: 11
  • Publication Date: 2012
  • Doi Number: 10.2174/138161212799504740
  • Title of Journal : CURRENT PHARMACEUTICAL DESIGN
  • Page Numbers: pp.1465-1477
  • Keywords: Anti-TNF therapy, cardiovascular diseases, disease-modifying anti-rheumatic drugs, HDL dysfunction, inflammation, lipoprotein(a), rheumatoid arthritis, HIGH-DENSITY-LIPOPROTEIN, SYSTEMIC-LUPUS-ERYTHEMATOSUS, APOLIPOPROTEIN-A-I, NECROSIS-FACTOR-ALPHA, C-REACTIVE PROTEIN, ACUTE MYOCARDIAL-INFARCTION, CONGESTIVE-HEART-FAILURE, INSULIN-RESISTANCE, ACCELERATED ATHEROSCLEROSIS, METABOLIC SYNDROME

Abstract

The article reviews the evidence and extent of the excess cardiovascular risk in patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and ankylosing spondylitis. RA entails nearly twice as high a standardized mortality ratio and is considered an equivalent of type 2 diabetes with regard to cardiovascular risk. The associated excess cardiovascular risk can only partly be explained by traditional risk factors, and the underlying inflammation is crucially involved in the pathogenesis.